The global migraine drugs market size was valued at USD 2000 million in 2021 and expected to reach USD 2527.40 million by 2028 growing at a CAGR of 3.4% during the forecast period from 2022 to 2028. Precision Business Insights published a research report on “Global Migraine Drugs Market by Drug Type, (Prophylactic, (Topiramate, Botulinum toxin), Abortive (Ergot Alkaloids, Triptans), By Route of Administration (Injectables, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Geography - Global/Region/Country Forecast to 2028”. The global migraine drugs market was valued at US$ 3.8 Bn in the year 2021 and is anticipated to record US$ 5.14 Bn till 2028 witnessing a CAGR of 4.4% over the forecast period 2022-2028.
View Detailed Report Description at https://precisionbusinessinsights.com/market-reports/global-migraine-drugs-market/
Growing Healthcare Expenses will Fuel the Global Migraine Drugs Market
Migraine is a headache disorder in which a person feels moderate to severe headache. Generally, migraine headache affects half of the head and last for 2 to 72 hours. Some common migraine symptoms are vomiting, nausea and sensitivity to sound, light and smell. Migraine drugs are available in the market to prevent precedence of a migraine, but no exact migraine therapy drugs are present in the market. One of the leading factors to drive the global migraine drugs market is increasing cases of migraine globally.
Anticipated commercialization of the pipeline drugs and growing RD activities by the key players for developing novel drugs are expected to impel the growth of the market during the forecast duration. But, availability of other treatments like neuromodulators and others and availability of the generic drugs are anticipated to hinder the global migraine drugs market growth over the forecast period. The market is experiencing a few mergers, collaborations, acquisitions and new product launches by industry players of the market. For example, Eli Lilly and Company acquired CoLucid pharmaceuticals, migraine Drugs Company in March 2017 for almost US$ 960 Mn. Likewise, Gralunenthal made an agreement in June 2017 for acquiring global rights for AstraZeneca’s migraine drug Zomig, outside japan market. In addition, there are several drugs in the market for treating migraine which are under development.
Regional Analysis:
On the basis of regional analysis, the market is classified into five major regions such as North America, Asia Pacific, Middle East, Europe, Latin America and Africa. Migraine drugs market in North America is expected to witness considerable growth rate due to the huge healthcare expenditure in the region. Asia Pacific migraine drugs market is anticipated to grow at significant growth rate over the forecast years because of the increasing consciousness about diagnosis and treatment of migraine. Emerging economies of Asia pacific such as India and China are projected to create profitable growth opportunities due to the changes in lifestyle.
Request sample report https://precisionbusinessinsights.com/request-sample?product_id=20614
Some of the major key players in the global migraine drugs market such as AstraZeneca Plc. (U.K.), Allergan Plc. (U.S.), Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline plc (U.K), Eli Lilly Co. (U.S.), Novartis AG (Switzerland), Merck Co., Inc. (U.S.), Valeant Pharmaceutical International, Inc. (Canada), Janssen Pharmaceutical Company (Johnson Johnson) (U.S.), Endo International plc. (U.S.), Zosano Pharma Inc. (U.S.), Alder Biopharmaceuticals (U.S.)
About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.
Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.
Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747
